Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Esperion Therapeutics reports robust Q4 earnings, eyes global expansion

Esperion Therapeutics delivered strong financial results in Q4 2022, driven by successful formulary additions and international partner growth.
The company faces challenges in increasing brand awareness and effectively positioning bempedoic acid post statins, requiring strategic marketing and market access initiatives.
Opportunities lie in leveraging upcoming trial results for label expansion, enhancing brand visibility, and capitalizing on international growth through partnerships.

Esperion Therapeutics excels in Q1 2023, poised for market opportunities

Esperion Therapeutics delivered robust Q1 results with revenue growth and positive market reactions to its studies. While facing legal challenges and operational discussions, the company is well-positioned to leverage opportunities in the market through its strong partnerships and financial stability.

Esperion Therapeutics excels in Q2 earnings, eyes label expansion opportunities

Esperion Therapeutics delivered strong financial performance in Q2 2023, driven by revenue growth, cost management, and strategic partnerships.
While facing challenges in managing expenses, the company is well-positioned to capitalize on market opportunities post-label expansion approvals.
With a solid cash position, ongoing operational efficiency efforts, and a focus on growth initiatives, Esperion is poised for continued success.
The company's commitment to innovation and patient outcomes bodes well for its future growth trajectory and market competitiveness.

Esperion Therapeutics excels in Q3 earnings amidst regulatory hurdles

Esperion Therapeutics delivered strong financial results in Q3 2023, driven by revenue growth and strategic collaborations, despite facing regulatory and litigation challenges.
The company's focus on expanding market presence through FDA approvals and international expansion presents promising growth avenues for future success.
With a solid financial position and ongoing initiatives to drive prescription growth, Esperion is poised to capitalize on market opportunities and navigate challenges effectively.

Esperion Therapeutics reports robust Q4 earnings and eyes market expansion

Esperion Therapeutics delivered strong financial performance in Q4 2023, showcasing significant revenue growth and strategic advancements.
While facing challenges in managing expenses and executing growth strategies, the company is well-positioned to capitalize on market opportunities and drive future expansion.
With a clear roadmap for expense management and a focus on product reach and market expansion, Esperion is poised for continued growth and value creation for stakeholders.
The settlement agreement and label expansion approvals provide a solid foundation for Esperion to leverage opportunities, overcome challenges, and drive sustainable growth.

Esperion Therapeutics posts robust Q1 results amid FDA label wins

Esperion Therapeutics delivered strong financial performance in Q1 2024, driven by revenue growth and FDA label expansions.
The company faces challenges in maintaining prescription growth and navigating payer dynamics post-label update.
Strategic initiatives and market opportunities present avenues for Esperion to capitalize on its recent successes and drive future growth.

Esperion Therapeutics reports robust Q2 revenue growth and global expansion

Esperion Therapeutics delivered strong financial performance in Q2 2024, driven by revenue growth and successful market expansion efforts.
While facing challenges such as debt extinguishment losses and high operating expenses, the company capitalized on opportunities for international growth and product marketability.
By leveraging strengths in expanded product labels and improved market access, Esperion is poised to navigate challenges and capitalize on growth opportunities in the pharmaceutical sector.

Esperion Therapeutics reports robust Q3 performance and eyes global expansion

Esperion Therapeutics delivered strong financial performance in Q3 2024, driven by revenue growth and strategic initiatives to expand market access and product offerings.
While challenges in achieving profitability persist, the company's focus on innovation, global expansion, and operational efficiency underscores its long-term growth potential.
By leveraging strengths in collaboration, research, and market differentiation, Esperion is poised to capitalize on opportunities for further international expansion and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position with $56 Million in Financing – – Global Regulatory Filings Anticipated in 1H 2023 – – Entered into Commercial Partnership with Currax Pharmaceuticals – ANN ARBOR, Mich., May 09, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Esperion Reports First Quarter 2023 Financial Results

ANN ARBOR, Mich., May 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP Securities Life Sciences Conference on Monday, May 15th, 2023 at 2:00 PM ET.

Esperion to Participate in JMP Securities Life Sciences Conference

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ANN ARBOR, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023.

Esperion to Report First Quarter 2023 Financial Results May 9, 2023

–  Performance-Based Agreement Provides for Currax's 72 Sales Representatives to Detail Esperion's Products –

Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC

Shattuck Labs

Verastem

Banco Bradesco

Tritium DCFC Ltd

ESS Tech

Momentus

Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price.

7 Very Undervalued Penny Stocks to Buy in April 2023

ANN ARBOR, Mich., April 03, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Needham's 22nd Annual Virtual Healthcare Conference on Monday, April 17th, 2023 at 8:45 AM ET.

Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference

Enovis Corp

Edgewise Therapeutics

Senseonics Holdings

SELLAS Life Sciences Group

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Preparing To Pump This Quarter - Enovis (NYSE:ENOV), Esperion Therapeutics (NASDAQ:ESPR)

BigBear.ai Holdings

iBio

Short squeeze penny stocks for your watch list. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 3 Short Squeeze Stock To Watch

ANN ARBOR, Mich., March 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”) today announced the closing of its previously announced registered direct offering of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 33,170,747 shares of common stock priced at-the-market under Nasdaq rules. Each share of common stock (or common stock equivalent in lieu thereof) was sold together with one short-term warrant to purchase one share of common stock at an effective combined purchase price of $1.675. The short-term warrants are immediately exercisable for a period of three and one half years and have an exercise price of $1.55 per share.

Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.

Esperion (ESPR) Plummets 54% Over Milestone Payment Row

The stock price of Esperion Therapeutics Inc (NASDAQ: ESPR) plummeted by 54.27% in the most recent trading session. This is why.

ESPR Stock: 54.27% Plummet Explanation

Esperion Therapeutics (NASDAQ: ESPR ) stock is taking a beating on Thursday as the company comes into conflict with Daiichi Sankyo Europe . The problem between these two companies has to do with milestone payments.

Why Is Esperion Therapeutics (ESPR) Stock Down 60% Today?

Shares of Esperion Therapeutics Inc. ESPR plunged about 56% in premarket trading on Thursday, the day after the company told investors that there is a dispute about a million milestone payment for its cholesterol-lowering treatment candidate worth up to $440 million. Esperion said earlier this month that Nexletol reduced the risk of heart attack and other heart issues in people who can't take statins.

Esperion's stock tumbles after disclosing dispute about milestone payment

Shares of Esperion Therapeutics (ESPR) fell last week as the company's cardiovascular outcome CLEAR study results failed to meet investor expectations.

Esperion Therapeutics (ESPR) Down 24% in a Week: Here's Why

BridgeBio Pharma Inc

At least two biotech stocks are seeing increased scrutiny in the options pits, with BridgeBio Pharma  Inc (NASDAQ:BBIO) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions following their respective drug updates.

2 Biotech Stocks Options Traders Are Watching

The stock of Esperion Therapeutics Inc. ESPR, -0.31% slumped 22% in premarket trade Monday, as investors seemed to question whether data from a major study of its cholesterol-lowering drug Nexletol showing it reduced the  risk of heart attacks and some other cardiovascular problems in people who can't tolerate statins would be enough to boost sales. Nexletol was granted approval by the U.S. Food and Drug Administration in February of 2020, but sales have been less than stellar.

Esperion Therapeutics stock slumps 22% premarket as data from study of cholestrol-lowering drug fail to impress investors

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin

Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients

Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion's Landmark CLEAR Outcomes Study, Company Pipeline and More Designed Specifically for the Scientific and Medical Communities, esperionscience.com Features Information about Esperion's Landmark CLEAR Outcomes Study, Company Pipeline and More

Esperion Launches New Scientific Website

Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.

Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down

ANN ARBOR, Mich., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a conference call and webcast on Monday, March 6th, 2023 where Esperion Chief Medical Officer Dr. JoAnne Foody and CLEAR Outcomes Principal Investigator Dr. Steven Nissen will discuss detailed results from CLEAR Outcomes, which are being presented at the American College of Cardiology Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC) on Saturday, March 4th, 2023.

CLEAR Outcomes Company Update Call: Detailed Results Discussion

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q4 2022 Earnings Conference Call February 21, 2023 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - President and Chief Executive Officer JoAnne Foody - Chief Medical Officer Benjamin Halladay - CFO Eric Warren - Chief Commercial Officer Conference Call Participants Serge Belanger - Needham Joseph Thome - Cowen Michael Yee - Jefferies Jason Butler - JMP Securities Jeff Hung - Morgan Stanley Tom Shrader - BTIG Jessica Fye - JPMorgan Judah Frommer - Credit Suisse Paul Choi - Goldman Sachs Operator Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today's conference call may be recorded.

Esperion Therapeutics, Inc. (ESPR) Q4 2022 Earnings Call Transcript

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.64% and 5.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Reports Q4 Loss, Misses Revenue Estimates

– Landmark CLEAR Outcomes Trial Successfully Completed and Met the Major Adverse Cardiovascular Events (MACE-4) Primary Endpoint and Additional Key Secondary Endpoints; Additional Details in 11 Days at ACC.23/WCC –

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

– NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint – – NEXLETOL® (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint –

News for Esperion Therapeutics Stock (ESPR)